(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 December 2020 (10.12.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/245365 A1

(51) International Patent Classification:
A61K 31/519 (2006.01) *A61P 35/00* (2006.01)
A61K 9/00 (2006.01) *A61K 45/06* (2006.01)

(21) International Application Number:
PCT/EP2020/065639

(22) International Filing Date:
05 June 2020 (05.06.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/858,076 06 June 2019 (06.06.2019) US
19193850.5 27 August 2019 (27.08.2019) EP

(71) Applicant: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, BE 2340 Beerse (BE).

(72) Inventors: **QUINN, Hillary Joy Millar**; 105 Rose Lane, Perkiomenville, Pennsylvania 18074 (US). **PACKMAN, Kathryn Elizabeth**; 255 Main Street, Cambridge, Massachusetts 02142 (US). **HADDISH-BERHANE, Nahor**; Welsh & McKean Rds., Spring House, Pennsylvania 19477 (US). **MANNENS, Geert S.J.**; Turnhoutseweg 30, BE 2340 Beerse (BE). **ZHOU, Junguo**; 1000 Route 202 South, Raritan, New Jersey 08869 (US). **GREWAY, Anthony T.**; 1000 Route 202 South, Raritan, New Jersey 08869 (US). **BREHMER, Dirk**; Turnhoutseweg 30, BE 2340 Beerse (BE). **GUO, Yue**; Welsh & McKean Rds., Spring House, Pennsylvania 19477 (US). **WU, Tongfei**; Karabiniersstraat 28, BE 3191 Hever (BE). **XIE, Hong**; Welsh & McKean Rds., Spring House, Pennsylvania 19477 (US). **LAURING, Josh**; Welsh & McKean Rds., Spring House, Pennsylvania 19477 (US).

(74) Agent: **WARNER, James Alexander** et al.; Carpmaels & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2020/245365 A1

(54) **Title:** METHODS OF TREATING CANCER USING PRMT5 INHIBITORS

(57) **Abstract:** The present disclosure provides methods for treating a human patient diagnosed with a cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, certain methods comprising (i) administering to the patient initial doses of at least about 0.1 mg per day of the PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3- d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable addition salt or solvate thereof for an initial dosing period of about 5 to about 21 days; and (ii) administering to the patient subsequent doses of at least about 0.1 mg per day of the PRMT5 inhibitor for one or more subsequent dosing periods of about 5 to about 21 days each. In these methods, a first subsequent dosing period is separated in time from the initial dosing period by at least about 5 days and the subsequent dosing periods are separated in time from each other by at least about 5 days.